A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Check Out Our Latest Stock Analysis on EDIT Editas Medicine Trading Down 2.1 % NASDAQ:EDIT opened at $1.38 on Friday. The company has a market capitalization of $113.92 million, a P/E ratio of -0. ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s President and CEO Gilmore O’Neill ...

Editas Medicine (EDIT) announced its three-year strategic priorities, anticipated 2025 key milestones, and new in vivo preclinical proof of concept data in non-human primates editing hematopoietic ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on the ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...

CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...

CAMBRIDGE, Mass. – Editas Medicine , Inc. (NASDAQ:EDIT), a leader in gene editing technology currently valued at $104 million in market capitalization, has unveiled significant advancements in ...

CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that the Company’s ...